glutamic acid diester hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glutamic acid diester hydrochloride
• 英文别名: 4-Amino-5-methoxy-5-oxopentanoic acid;hydrochloride；4-amino-5-methoxy-5-oxopentanoic acid;hydrochloride
• 化学式: C₆H₁₁NO₄*ClH
• 分子量: 197.619
• InChiKey: QXMRXPZMEBBMNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.23
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  89.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  glutamic acid diester hydrochloride 在 sodium tetrahydroborate 、 碳酸氢钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 (S)-methyl 4-(tert-butoxycarbonylamino)-5-hydroxypentanoate
  参考文献：
  名称：

  Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

  摘要：

  An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.04.069
• 作为产物：
  描述：

  甲醇 、 DL-谷氨酸 在 盐酸 作用下， 以100%的产率得到glutamic acid diester hydrochloride
  参考文献：
  名称：

  Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

  摘要：

  An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.04.069

文献信息

• Simple and effective preparation of amino sulfonylureas from amino acids: application to the synthesis of amino sulfonylurea-containing peptidomimetics
  作者：Roman Šink、Anamarija Zega

  DOI：10.1016/j.tetlet.2008.04.047

  日期：2008.6

  Several amino sulfonylureas have been synthesized, starting from amino acids. The synthetic procedure is simple affording high yields of products under mild conditions. Furthermore, it is shown that these compounds can be incorporated into a peptide sequence. (c) 2008 Elsevier Ltd. All rights reserved.
• DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1001971A1

  公开（公告）日：2000-05-24
• LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS
  申请人：Albany Molecular Research, Inc.

  公开号：EP2968599A1

  公开（公告）日：2016-01-20
• [EN] DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4<br/>[FR] COMPOSES DE DIPEPTIDES ET ASSOCIES INHIBANT UNE ADHESION DE LEUCOCYTES REGULEE PAR VLA-4
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：WO1999006432A1

  公开（公告）日：1999-02-11

  (EN) Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brains diseases such as multiple sclerosis.(FR) L'invention concerne des composés se liant à VLA-4. Certains de ces composés inhibent également une adhésion de leucocytes et, notamment, une adhésion de leucocytes régulée par VLA-4. Ces composés s'utilisent dans le traitement d'affections inflammatoires chez un patient mammalien, par exemple un humain, l'affection consistant par exemple en asthme, maladie d'Alzheimer, athérosclérose, syndrome démentiel du SIDA, diabète, affection intestinale inflammatoire, polyarthrite rhumatoïde, transplantation de tissus, métastase tumorale et ischémie myocardique. Les composés peuvent également être administrés pour le traitement d'affections cérébrales inflammatoires telles que la sclérose en plaques.
• [EN] LIGAND-THERAPEUTIC AGENT CONJUGATES AND SILICON-BASED LINKERS<br/>[FR] CONJUGUÉS LIGAND-AGENT THÉRAPEUTIQUES ET LIEURS À BASE DE SILICIUM
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2014160305A1

  公开（公告）日：2014-10-02

  The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.